Patients with Early Initiation of DLI for Mixed Donor Chimerism Were More Likely to Have Improvement in Donor Chimerism  by Haines, H.L. & Filipovich, A.H.
Oral Presentations S231GVHD in recipients of UCBT, we extended our analysis of patients
in our earlier study to determine rates of GVHDpersistence, contin-
ued immunosuppressive therapy, and survival at 1, 2 and 3 years
post-UCBT. A total of 81 patients were enrolled on our local,
IRB-approved UCBT trial between January 1996 and July 2007. Se-
venty-nine percent (54/68) of patients had malignant diagnoses and
21% (14/68) had nonmalignant disorders. Thirteen patients were ex-
cluded from analysis due to death prior to engraftment (7), graft re-
jection (4), or re-transplant during the follow-up period (2). Median
age of evaluable patients was 7.2 years (Range, 0.3-24.4years).
Among the 68 evaluable patients, 40 (59%) developed GVHD fol-
lowing UCBT. Based on Seattle criteria, 36 patients (53%) experi-
enced Grade I-IV acute GVHD with 17 (25%) classified as Grade
III-IV. Chronic GVH occurred in 21 of 58 patients (36%) surviving
beyond Day 100, including 4 with de novo chronic GVH. Chronic
GVHD was limited in 2 patients and extensive in 19. No new onset
chronic GVH was seen beyond 1 year post-transplant. In patients
with prior GVHD, persistent GVHD activity was present in 28%
(7/25), 14% (3/22) and 0% (0/20) of patients at 1, 2 and 3 years
post-UCBT. Among those with prior GVHD, 68% (17/25), 41%
(9/22) and 10% (2/20) of patients remained on one or more systemic
immunosuppressive medications at 1, 2 and 3 years post-UCBT.
Survival of patients with prior GVHD was 63% (25/40), 55% (22/
40) and 50% (20/40) at 1, 2 and 3 years post-UCBT. We conclude
that the course of GVHD following UCBT is both more manage-
able, i.e.-not associated with increased mortality, and resolves in
nearly all patients by 3 years post-UCBT allowing discontinuation
of immunosuppressive therapy. These features of GVHD in
UCBT appear to differentiate this product from adult unrelated
stem cell sources.
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ENCOURAGING RESULTS WITH THE USE OF FLUDARABINE BASED CON-
DITIONING REGIMENS IN CHILDRENWITH ACQUIRED AND CONGENITAL
BONE MARROW FAILURE SYNDROMES (BMFS)
George, B., Mathews, V., Ahmed, R., Abraham, A., Srivastava, A. Chris-
tian Medical College, Vellore, Tamilnadu, India
Between July 1999 and June 2011, sixty children (39 male and 21
female) with acquired and congenital BMFS underwent HLA iden-
tical stem cell transplantation (HSCT) using a fludarabine based
protocol. This included 39 patients with acquired aplastic anemia
(AA), 19 with Fanconi’s anemia (FA) and 2 with dyskeratosis conge-
nita (DKC). Three patients with FA hadmyelodysplastic syndromes.
The conditioning protocol used for AAwas Fludarabine (180mg/m2
over 6 days), Cyclophosphamide (120mg/kg over 2 days) + Anti- thy-
mocyte globulin (40mg/kg over 4 days). In patients with FA and
DKC, the dose of cyclophosphamide was reduced to 20 mg/kg and
in 3 patients with MDS, cyclophosphamide was replaced by busul-
fan. Cyclosporine with mini methotrexate was used for GVHD pro-
phylaxis. Graft source included peripheral blood stem cells (44) or
G-CSF stimulated bone marrow (16).
Fifty six patients engrafted (93.3%) while 2 patients with AA had
primary graft failure and 2 expired\2 weeks post HSCT. The me-
dian time to neutrophil engraftment was 14 days (range: 9 – 29) while
median time to platelet engraftment was 11 days (range: 7 – 31). Four
patients with FA/DKC and 2 patients with AA had secondary graft
rejection. Incidence of acute GVHD was 20% in children with AA
while it was 28.5% in children with congenital BFMS. Chronic
GVHD was seen in 33.3% of AA and 40% of children with congen-
ital BFMS. Three childrenwith AA and 3 with FA/DKChave under-
gone a second transplant using the same donor. The 2 year overall
survival is 83.3%with a survival of 87.1% in children with idiopathic
AA and 76.2% in children with congenital BFMS.
Fludarabine based protocols are associated with excellent survival
in children with acquired and congenital bone marrow failure syn-
dromes.
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OUTCOME OF MIXED CHIMERISM IN CHILDREN UNDERGOING ALLOGE-
NEIC STEM CELL TRANSPLANT (HSCT) FOR THALASSEMIA MAJOR
George, B., Mathews, V., Sindhuvi, E., Jain, S., Ahmed, R.,
Abraham, A., Srivastava, A. Christian Medical College, Vellore, Tamil-
nadu, IndiaA number of patients develop mixed chimerism following HSCT
for thalassemia despite the use of myeloablative chemotherapy. This
study analysed the outcome of mixed chimerism in children who un-
derwent allogeneic HSCT for thalassemia.
Between Jan 1995 to June 2011, 265 children underwent HLA
identical allogeneic HSCT for thalassemia using sibling or family
donors where chimerism data was available. Patients had chimerism
analysis performed using VNTRs performed initially at day 30 and
then as required. Mixed chimerism (MC) was graded as per Nesci
et al into level I (host cells\10%), level II (host cells 10-30%) or
level III (. 30%). Complete chimerism was the presence of\5%
host cells. Therapeutic interventions included taper of immunosup-
pression or use of donor lymphocyte infusion.
Seventy patients (26.4%) developed mixed chimerism either at
Day 30 or during subsequent follow up. Thirty five patients (50%)
had level I, 14 (20%) had level II and 8 (11.4%) had level III MC
while 13 (18.6%) had complete chimerism (CC) on day 30 but sub-
sequently developed MC. Of the 35 patients with Level 1 MC, 14
achieved CC while 17 (70%) had stable mixed chimerism (3 re-
mained at level 1; 4 progressed to level II or III) and 4 (11.4%) re-
jected. Of the 14 with Level 1I MC, 2 (14.2%) achieved CC, 6
(42.8%) had stable mixed chimerism with transfusion independence
and 6 (42.8%) rejected. Among 8 patients with level III chimerism, 6
(75%) rejected while 1 achieved CC after a DLI and 1 remained at
level III but remained transfusion independent. Thirteen patients
achieved CC by Day +30 but subsequently lost their chimerism - 2
dropped to level I, 5 to level II, 6 to level III. Of these, 11 (84.6%)
are either in CC or have stable mixed chimerism while 2 (15.4%)
had secondary rejection.
There is an increased risk of secondary rejection in patients with
level II and III MC at Day 30 following allogeneic HSCT for thal-
assemia. Newer strategies need to be adopted to reduce graft rejec-
tion in these patients.
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PATIENTS WITH EARLY INITIATION OF DLI FOR MIXED DONOR CHIME-
RISM WERE MORE LIKELY TO HAVE IMPROVEMENT IN DONOR CHIME-
RISM
Haines, H.L.1, Filipovich, A.H.2 1University of Alabama Birmingham,
Birmingham, AL; 2Cincinnati Children’s Hospital Medical Center, Cin-
cinnati, OH
Background: Increased use of reduced intensity conditioning regi-
mens in the pediatric setting mean more patients will require T
cell donor lymphocyte infusion (DLI) for mixed donor chimerism.
A retrospective review of 33 patients (age # 21 years) who received
DLI as primary cellular therapy for mixed chimerism from 2006 to
2010 was conducted.
Patients andmethods:Most patients underwent hematopoietic cell
transplant (HCT) for non-malignant disease after a preparative reg-
imen consisting of alemtuzumab, fludarabine andmelphalan. Indica-
tions for HCT were immune deficiency (29), Fanconi Anemia (1),
Hurler’s (1), Langerhans Cell Histiocytosis (1), and myelodysplasia
(1). Patients received DLI for mixed chimerism after reduction in
immune suppression was ineffective.
Results: Patients received a mean of 3.2 DLIs (range 1-12). Mean
first T cell dose was 2.6 X 106 cells/kg; mean total T cell dose was
5.8 X 107 cells/kg. Average donor chimerism prior to first DLI was
42%. Sixteen patients (48%) had increase from pre-DLI donor chi-
merism of $ 20% within eight weeks of DLI and were classified as
responders. Response was seen at a mean of 21 days after DLI (range
1-42) with peak donor chimerism seen at 51 days. Complete response
(peak donor chimerism of .99%) was seen in eleven patients. One
patient had graft versus host disease (GVHD) prior to DLI. Ten pa-
tients, all responders, developedGVHDafterDLI. GVHDwas gen-
erally mild with only two patients having $ grade 3.
When responders were compared with non-responders (Table 1)
there was no difference in donor chimerism prior to DLI therapy,
number of DLIs, or total and initial T cell doses. However, re-
sponders received their first DLI earlier after HCT, likely due to re-
sponders’ tendency toward earlier loss of donor chimerism after
HCT and shorter lag time between decreased donor chimerism
and first DLI. Response rates were higher for patients who received
DLI early after donor chimerism drop. Patients who received first
DLI # 50 days after loss of donor chimerism (N 5 17) had a 71%
response rate; patients who received DLI . 50 days (N 5 13) after
S232 Oral Presentationsinitial loss of donor chimerism had a 31% response rate. No re-
sponses were seen in four patients who received their first DLI .
100 days after loss of donor chimerism. Three patients had insuffi-
cient data to determine timing of decrease in donor chimerism.
Conclusions: Prompt initiation of DLI for mixed chimerism in-
creases the likelihood of improvement in donor chimerism.
Table 1. T Cell Donor Lymphocyte Infusion for Mixed Donor
Chimerism: Characteristics for Responders Compared to
Non-responders
Responders Non-respondersTable.
Patient/Dgn Donor(Match) A
1 / HLH URD (7/8)
2 / XLP MSD (8/8)
3 / XLP URD (7/8)
4 / FA MUD (8/8)
5 / CML MUD (8/8)
HLH: hemophagocytic lymphohist
URD: unrelated donor; MSD: mat
megalovirus; EBV: Epstein-Barr vir(N 5 16)ge (y)
0.6 Blo
1.8 Blo
N
1.8 Blo
5.8 Blo
10.4 Blo
iocytosis; XL
ched sibling d
us, adeno: a(N 5 17)Infections
od-CMV; NS-none
od-adeno;
S-metapneumovir
od-none; NS-none
od-none; BAL-non
od-BK; BAL-EBV
P: X-linked lymp
onor; MUD: mat
denovirus; BK-BKp valueMean # of T cell doses 2.8 ± 3.1 3.6 ± 2.0 0.36
Mean first T cell dose (X 106) 2.4 ± 4.8 2.8 ± 3.4 0.56
Mean total T cell dose (X 107) 5.7 ± 11.1 5.9 ± 10.2 0.95
Days post transplant for first DLI 86 ± 41 143 ± 48 0.0007
Days post transplant for initial
chimerism drop of at least 10%41 ± 26 72 ± 65 0.09Days between chimerism
drop and first DLI42 ± 27 82 ± 51 0.008Last engraftment prior to first DLI 39 ± 22 45± 16 0.4
Acute GVHD following DLI 10 (62.5%) 080
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC PA-
TIENTS WITH HEREDITARY BONE MARROW FAILURE SYNDROMES
WITHOUT TOTAL BODY IRRADIATION
Hamidieh, A.A., Behfar, M., Hamdi, A., Ostadali, M.R., Jalili, M.,
Jalali, A., Hosseini, A., Basirpanah, S., Ghavamzadeh, A. Tehran Uni-
versity of Medical Sciences, Tehran, Islamic Republic of Iran
Background: Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) remains as the treatment of choice to correct the hema-
tological abnormalities in patients with Fanconi anemia (FA) andDi-
amond-Blackfan anemia (DBA). The aim of this study is to analyze
the outcomes of allo-HSCT on FA and DBA at our center.
Methods: We prospectively analyzed the outcomes of 33 patients
with FA and 7 patients with DBA (25 male and 15 female) who
had undergone allo-HSCT between January 2008 and September
2011 in our institution. The median age at transplantation was 8
years (age range, 1-14 years). Conditioning regimen consisted of bu-
sulfan (0.2 mg/kg/day for 4 consecutive days in divided doses) plus
cyclophosphamide (15mg/kg/day intravenously for 4 days) in FA pa-
tients and busulfan (4 mg/kg/day for 4 consecutive days in divided
doses) plus cyclophosphamide (50 mg/kg/day intravenously for 4
days) in DBA patients. Twenty patients received horse antithymo-
cyte globulin (10 mg/kg intravenously). No radiation therapy was
given. Thirty four patients received transplants fromHLA-matched
donors (23 from sibling and 11 from other related donors), five pa-
tients received transplants from one-antigen locus mismatched do-
nors and one patient received cord blood stem cell from partially
matched unrelated donor. Cyclosporine and methotrexate were
used as Graft-versus-host disease (GVHD) prophylaxis.
Results: The median time to neutrophil engraftment was 11 days
(range, 8-28 days) and the median time to platelet engraftment was
19 days (range, 9-61 days). The 6-month survival rate was 88.5%Days fro
to
us
e
hoproliferative
ched unrelate
virus; echo: e(SE 5 6.3%) for FA patients and 75% (SE 5 21.7%) for DBA pa-
tients. Thirty one patients developed acute GVHD (23, grade I-II
and 8, grade III-IV). Three deaths and one rejection occurred among
FA patients and one DBA patient died at a median follow-up of 6
months (range 1-41months). The causes of deaths were failure of en-
graftment, renal failure and sepsis in FA and acute GVHD grade IV
in DBA.
Conclusion: Despite the high incidence of aGVHD in our study,
overall survival in our study was comparable with other studies advo-
cating fludarabine-based regimen in hereditary bone marrow failure
syndromes. Therefore, we propose to conduct a multicenter, pro-
spective study to evaluate the outcome of regimens employed in he-
reditary bone marrow failure syndromes.
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PULMONARY HYPERTENSION (PH) IN PATIENTS WITH HEMATOPOIETIC
STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOP-
ATHY (TMA)
Jodele, S.1, Chima, R.2, Hor, K.3, Witte, D.4, Laskin, B.L.5, Goebel, J.5,
Mayers, K.C.1, Mehta, P.A.1, Filipovich, A.H.1, Marsh, R.A.1,
Grimley, M.S.1, Davies, S.M.1 1Cincinnati Children’s Hospital Medical
Center, Cincinnati, OH; 2Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH; 3Cincinnati Children’s Hospital Medical Center, Cincin-
nati, OH; 4Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH; 5Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Pulmonary hypertension is rarely included in the differential diag-
nosis of respiratory failure following pediatric hematopoietic stem
cell transplant (HSCT) as the clinical presentation is non-specific
and may mimic other causes of respiratory failure. Hence, this diag-
nosis requires a high degree of suspicion.Moreover, the etiology and
pathogenesis of PH in HSCT are poorly understood.We describe 5
allogeneic HSCT patients that had TMA and developed hypoxemic
respiratory failure with evidence of PH. All 5 patients had active
signs of TMA (microangiopathic anemia, hypertension, proteinuria)
when presented with hypoxemia that progressed to respiratory fail-
ure requiring mechanical ventilation. Notably, at presentation there
was no significant radiographic evidence of lung disease. Three pa-
tients had long standing viremias and two were diagnosed with viral
pathogens in respiratory secretions (Table). On echocardiography 4
of 5 patients had echocardiographic evidence of PH (right ventricu-
lar dysfunction, dilation and/or elevated right ventricular pressure).
One patient was diagnosed with PH on autopsy. Median presenta-
tion of PH after TMA diagnosis was 76d (range 56-101d). Despite
aggressive medical management including inhaled nitric oxide
(iNO) 4 of 5 patients died. One patient recovered from PH after
11 month of sildenafil therapy. Three of the 4 deceased patients
had autopsy done that demonstrated severe pulmonary vasculopathy.
Specifically, lung histology demonstrated severe acute and subacute
TMA as evidenced by endothelial separation in the pulmonary arte-
rioles with fragmented red blood cell extravasation into the intimal
layer and formation of fibrin thrombi. These findings were associ-
ated with marked thickening of all three layers of the vascular wall
with up to 95% occlusion of the arteriolar lumens diagnostic for
PH. Although post-HSCT TMA usually affects renal vessels, it
can also be associated with significant pulmonary vascular injury pre-
senting as hypoxemic respiratory failure with PH following HSCT.
In conclusion, HSCT patients with unexplained hypoxemia and re-
spiratory failure should be evaluated for TMA and PH accordingly.m HSCT (day 0)
TMA/PH Therapy Status Lung Biopsy (B) or Autopsy (A)
132/208 iNO Dead A: Severe TMA and
PE. In situ +CMV
15/71 iNO Dead A: Severe TMA and PE
91/169 iNO Dead A: Severe TMA and PE
17/79 iNO Dead Autopsy not done
149/250 Sildenafil Alive B: Constrictive bronchiolitis,
mild vasculopathy
syndrome; FA: Fanconi anemia; CML: chronic myelogenous leukemia;
d donor; NS: nasal secretions; BAL: bronchoalveolar lavage; CMV: cyto-
chocardiography; path: pathology evaluation; iNO: inhaled nitric oxide.
